November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO
Feb 9, 2024, 17:42

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Centre, shared an X post by Hassan Abushukair, a medical student at the Jordan University of Science and Technology:

“Happy to share these two papers out today in the same issue of JCO Precision Oncology – ASCO:

1) multi omics work on Stk11 NSCLC with Caris Life Sciences,
and
2) biomarker prediction in irAEs using machine learning and omics approaches (thread below). Lots of people to thank / Hassan Abushukair, Caris Life Sciences.

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

 

Quoting Hassan Abushukair’s post:

“Excited to announce the publication of our paper on TIME features and irAEs in JCOPO_ASCO!
Can’t thank Dr. Rafeh Naqash enough for this opportunity and his mentorship. Huge shout out to the all-star team, learned a lot from you guys!
Tweetorial below:”

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Contrary to ICI efficacy, there is limited research dissecting determinants of ICI toxicity.
We aimed to provide insights into potential TIME parameters correlating with ICI irAEs (anti-PD-1/L1/CTLA-4) across 33 cancer types using clinical, omics and digital pathology data.

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Clinical data:
Using the US FDA FAERS database, 58,961 ICI-treated pts were identified, 25.6% had irAEs, of which 41.2% had serious irAEs.
Colitis highest incidence in melanoma (9.7%),
Pneumonitis highest incidence in NSCLC (4.5%).

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Clinical Data:
Through 75 clinical trials encompassing 18,512 melanoma/NSCLC ICI-treated patients further confirmed these results.”

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Transcriptomics analysis of TIME features:
Using bulk RNA-seq data from TCGA, reporting OR (RORs) were calculated for 33 TIME features
+ve correlations were reported between irAE RORs and median CD8+ T cells fraction, INDEL and SNV neoantigens.

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Transcriptomics analysis of TIME features:
A composite model consisting of median number of INDEL neoantigens and CD8+ T cells fraction had superior irAE ROR predictive performance.
Notably, myocarditis and myositis both were associated with INDEL load.

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Digital pathology:
Using a cohort of 156 ICI-treated NSCLC pts from DFCI who underwent multiplexed immunofluorescence staining:
There was a trend for higher baseline median CD8+ T cells and irAEs.
Yet, baseline PD-L1 status did not correlate with irAEs.

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Digital pathology:
Through another cohort of 378 ICI-treated NSCLC patients, using a machine learning approach for H&E-based TILs detection:
We further confirmed the correlation between baseline median TILs and irAEs development.

Rafeh Naqash: Happy to share these two papers out today in the same issue of JCOPO_ASCO

Incredibly thankful and proud to be part of such important collaborative work that truly embodies the spirit of global alliance!
A huge shoutout to the entire team who made this possible.

View additional information.
Source: Rafeh Naqash/X and Hassan Abushukair/X